Health insurance company Clover Health (NASDAQ:CLOV) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 33.3% year on year to $462.3 million. Its non-GAAP profit of $0.05 per share was significantly above analysts’ consensus estimates.
Home and security products company Fortune Brands (NYSE:FBIN) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 6.9% year on year to $1.03 billion. Its non-GAAP profit of $0.66 per share was in line with analysts’ consensus estimates.
Medical tech company Masimo (NASDAQ:MASI) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.5% year on year to $372 million. The company expects the full year’s revenue to be around $1.52 billion, close to analysts’ estimates. Its non-GAAP profit of $1.36 per share was 12.6% above analysts’ consensus estimates.
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 80.2% year on year to $744.9 million. Its non-GAAP loss of $3.42 per share was significantly below analysts’ consensus estimates.
Senior living provider The Pennant Group (NASDAQ:PNTG) announced better-than-expected revenue in Q1 CY2025, with sales up 33.7% year on year to $209.8 million. Its non-GAAP profit of $0.27 per share was 13.7% above analysts’ consensus estimates.
Heaf was previously Nike’s chief strategy and transformation officer, but his position was eliminated as part of CEO Elliot Hill's transformation efforts.
Higher education company Grand Canyon Education (NASDAQ:LOPE) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 5.3% year on year to $289.3 million. The company expects next quarter’s revenue to be around $240.3 million, close to analysts’ estimates. Its GAAP profit of $2.52 per share was 2.9% above analysts’ consensus estimates.
Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the midpoint came in 3.7% below analysts’ estimates. Its non-GAAP loss of $0.03 per share was $0.02 above analysts’ consensus estimates.
Cross border payment processor Flywire (NASDAQ: FLYW) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 17% year on year to $133.5 million. The company expects next quarter’s revenue to be around $124.4 million, close to analysts’ estimates. Its non-GAAP profit of $0.11 per share was in line with analysts’ consensus estimates.
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $4.28 billion at the midpoint. Its non-GAAP profit of $1.68 per share was 63.9% below analysts’ consensus estimates.
Wellness products company Nature’s Sunshine (NASDAQ:NATR) announced better-than-expected revenue in Q1 CY2025, with sales up 2% year on year to $113.2 million. The company expects the full year’s revenue to be around $457.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.25 per share was 51.5% above analysts’ consensus estimates.
Technology real estate company Opendoor (NASDAQ:OPEN) announced better-than-expected revenue in Q1 CY2025, but sales fell by 2.4% year on year to $1.15 billion. On the other hand, next quarter’s revenue guidance of $1.49 billion was less impressive, coming in 0.8% below analysts’ estimates. Its non-GAAP loss of $0.09 per share was 15.9% above analysts’ consensus estimates.
